$HQY

Wellborn Gayle Furgurson sold $220K of HQY

Wellborn Gayle Furgurson sold 2,439 shares of HEALTHEQUITY, INC. (HQY) at $90.00 ($0.22M total) on 2026-05-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Wellborn Gayle Furgurson
Published Jun 1, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 1, 2026, 10:05 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$HQY
Neutral
medium confidence
Mentioned
$HQY
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$HQYNeutralLow
01

Why it matters

The disclosure may slightly influence sentiment, but it is unlikely to change valuation materially absent other company-specific news.

02

Market read

Traders may note the insider sale for sentiment tracking, but the 10b5-1 designation reduces the likelihood of a meaningful price reaction.

03

What to watch

The filing doesn’t reveal intent beyond the plan; without a pattern of repeated sales or size relative to holdings, signal strength is limited.

Relevance 6/10Novelty 6/10Timing: Filed today; sale occurred 2026-05-28 (10b5-1 plan).

Background

SEC Form 4 reports insider transactions; this one is an open-market sale by a director with a stated 10b5-1 pre-arranged plan.

Company-level read

Ticker impact

$HQYNeutralMedium confidence
Context

Director Wellborn Gayle Furgurson sold 2,439 shares in an open-market transaction at $90.00/share, disclosed via SEC Form 4.

Expected impact

Likely limited near-term impact; any effect should be small versus broader fundamentals.

Evidence & confidence

This is an ownership-change disclosure without accompanying operational or financial catalyst; 10b5-1 pre-arrangement typically dampens signaling value.

Market effects

Minimal; single-company insider transaction with no sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect routine liquidity needs rather than bearish expectations.

Key entities

  • HEALTHEQUITY, INC.

    HQY, subject of the insider transaction disclosure.

  • Wellborn Gayle Furgurson

    Director who sold shares under an open-market transaction and 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$HQYHighAI 8/10

HealthEquity (HQY) Q2 2027 Earnings Call Transcript

HealthEquity (HQY) reported Q2 2027 revenue of $350.7M, up 8% YoY, and adjusted EBITDA of $167M, up 11%. HSA assets grew 14% to $37.9B. The company raised full-year revenue guidance to $1.411B-$1.421B and adjusted EBITDA to $628M-$636M. Management highlighted growth in custodial and service revenue, as well as operational efficiencies from AI and technology investments.

$HQYMed

Why HealthEquity Stock Sank This Week

HealthEquity (HQY) stock fell 8.6% this week despite beating earnings and revenue estimates for Q2. The company reported adjusted EPS of $1.24 on revenue of $350.7M, up 15.7% and 7.6% YoY, respectively. Investors expected stronger guidance, as the company only slightly raised its full-year revenue target and reiterated EPS guidance.